+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2017

  • ID: 4189178
  • Report
  • March 2017
  • 152 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • Celgene Corp
  • Dynavax Technologies Corp
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • MedImmune LLC
  • MORE
B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2017, provides an overview of the B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.

B-Cell Chronic Lymphocytic Leukemia is a type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms or in the groin, pain or discomfort under the ribs on the left side, due to an enlarged spleen, frequent or repeated infections and slow healing, due to a lack of normal white blood cells, excessive sweating at night and unintentional weight loss. Treatment includes chemotherapy and radiation.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 7, 12 and 3 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 3 and 2 molecules, respectively.

B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • AB Science SA
  • Celgene Corp
  • Dynavax Technologies Corp
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • MedImmune LLC
  • MORE
Introduction

B-Cell Chronic Lymphocytic Leukemia - Overview

B-Cell Chronic Lymphocytic Leukemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development

AB Science SA

Aduro BioTech Inc

BioInvent International AB

Boehringer Ingelheim GmbH

Celgene Corp

Cell Source Inc

Cellectis SA

Dynavax Technologies Corp

Eisai Co Ltd

Elsalys Biotech SAS

F. Hoffmann-La Roche Ltd

iDD biotech SAS

Immunomedics Inc

Johnson & Johnson

Juno Therapeutics Inc

Lymphocyte Activation Technologies SA

Mabion SA

MedImmune LLC

MEI Pharma Inc

Millennium Pharmaceuticals Inc

Molecular Templates Inc

Noxxon Pharma AG

Ono Pharmaceutical Co Ltd

Regeneron Pharmaceuticals Inc

Sunesis Pharmaceuticals Inc

Unum Therapeutics Inc

B-Cell Chronic Lymphocytic Leukemia - Drug Profiles

202-b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-8779 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alemtuzumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alisertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-1206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-836826 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BION-1301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Chronic Lymphocytic Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Hematological Malignancies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD19 for B-Cell Malignancies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DTRMWXHS-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-7449 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ELB-021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDD-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDD-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-64052781 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lenalidomide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ME-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mRNA ACTR + rituximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-3724 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olaptesed pegol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-1979 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SD-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNS-062 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAB-08 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tirabrutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UCART-22 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UCARTCS-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-Cell Chronic Lymphocytic Leukemia - Dormant Projects

B-Cell Chronic Lymphocytic Leukemia - Discontinued Products

B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones

Featured News & Press Releases

Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on SNS-062

Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement

Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Target, H1 2017 (Contd..1), H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Aduro BioTech Inc, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioInvent International AB, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Boehringer Ingelheim GmbH, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corp, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Cell Source Inc, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Cellectis SA, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corp, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Eisai Co Ltd, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Elsalys Biotech SAS, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by F. Hoffmann-La Roche Ltd, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics Inc, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Johnson & Johnson, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Lymphocyte Activation Technologies SA, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Mabion SA, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by MedImmune LLC, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by MEI Pharma Inc, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Millennium Pharmaceuticals Inc, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Molecular Templates Inc, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co Ltd, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals Inc, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Sunesis Pharmaceuticals Inc, H1

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Unum Therapeutics Inc, H1

B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H1

B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H1 2017 (Contd..1), H1

B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H1

List of Figures:

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
4 of 5
  • AB Science SA
  • Aduro BioTech Inc
  • BioInvent International AB
  • Boehringer Ingelheim GmbH
  • Celgene Corp
  • Cell Source Inc
  • Cellectis SA
  • Dynavax Technologies Corp
  • Eisai Co Ltd
  • Elsalys Biotech SAS
  • F. Hoffmann-La Roche Ltd
  • iDD biotech SAS
  • Immunomedics Inc
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Lymphocyte Activation Technologies SA
  • Mabion SA
  • MedImmune LLC
  • MEI Pharma Inc
  • Millennium Pharmaceuticals Inc
  • Molecular Templates Inc
  • Noxxon Pharma AG
  • Ono Pharmaceutical Co Ltd
  • Regeneron Pharmaceuticals Inc
  • Sunesis Pharmaceuticals Inc
  • Unum Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll